CA3071315A1 - Dual mode radiotracer and -therapeutics - Google Patents
Dual mode radiotracer and -therapeutics Download PDFInfo
- Publication number
- CA3071315A1 CA3071315A1 CA3071315A CA3071315A CA3071315A1 CA 3071315 A1 CA3071315 A1 CA 3071315A1 CA 3071315 A CA3071315 A CA 3071315A CA 3071315 A CA3071315 A CA 3071315A CA 3071315 A1 CA3071315 A1 CA 3071315A1
- Authority
- CA
- Canada
- Prior art keywords
- bond
- oligo
- conjugate
- acid
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17183795.8 | 2017-07-28 | ||
| EP17183795 | 2017-07-28 | ||
| PCT/EP2018/070533 WO2019020831A1 (en) | 2017-07-28 | 2018-07-30 | AGENTS WITH TWO RADIOTRATIVE AND THERAPEUTIC MODES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3071315A1 true CA3071315A1 (en) | 2019-01-31 |
Family
ID=59501286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3071315A Pending CA3071315A1 (en) | 2017-07-28 | 2018-07-30 | Dual mode radiotracer and -therapeutics |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US11413360B2 (https=) |
| EP (3) | EP4000640A1 (https=) |
| JP (2) | JP7059372B2 (https=) |
| KR (2) | KR102752620B1 (https=) |
| CN (1) | CN111132700B (https=) |
| AU (2) | AU2018308699B2 (https=) |
| BR (1) | BR112020001785A2 (https=) |
| CA (1) | CA3071315A1 (https=) |
| DK (1) | DK3658194T3 (https=) |
| EA (1) | EA202090370A1 (https=) |
| ES (1) | ES3011272T3 (https=) |
| FI (1) | FI3658194T3 (https=) |
| HU (1) | HUE070098T2 (https=) |
| IL (2) | IL318092A (https=) |
| MX (2) | MX2020000352A (https=) |
| NZ (1) | NZ760537A (https=) |
| PL (1) | PL3658194T3 (https=) |
| PT (1) | PT3658194T (https=) |
| SG (1) | SG11202000725WA (https=) |
| WO (1) | WO2019020831A1 (https=) |
| ZA (1) | ZA202000467B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202090370A1 (ru) | 2017-07-28 | 2020-05-25 | Технише Универзитет Мюнхен | Двухрежимная радиоактивная метка и радиотерапевтическое средство |
| IL303420A (en) * | 2019-01-30 | 2023-08-01 | Univ Muenchen Tech | Diagnostic imaging materials for cancer |
| CN113677375B (zh) * | 2019-01-30 | 2024-07-23 | 慕尼黑工业大学 | 氟化硅受体取代的放射性药物及其前体 |
| EP3917626B1 (en) * | 2019-01-30 | 2023-05-31 | Technische Universität München | Psma binding dual mode radiotracer and therapeutic |
| CN112168978B (zh) * | 2019-07-03 | 2022-01-11 | 北京大学 | 一种抗体偶联药物及其药物组合物与应用 |
| WO2021086917A1 (en) * | 2019-10-29 | 2021-05-06 | The Cleveland Clinic Foundation | Psma-targeting imaging agents |
| CN113350531A (zh) * | 2020-03-02 | 2021-09-07 | 上海核力星医药科技有限公司 | 前列腺特异性膜抗原结合配体偶联物及其应用 |
| GB202005282D0 (en) * | 2020-04-09 | 2020-05-27 | Blue Earth Diagnostics Ltd | Pharmaceutical Formulations |
| WO2022018264A1 (en) | 2020-07-23 | 2022-01-27 | Technische Universität München | Silicon-containing ligand compounds |
| CN116583527A (zh) | 2020-09-03 | 2023-08-11 | 库瑞姆美国有限责任公司 | 用于64Cu-DOTATATE放大规模的放射性标记和制剂 |
| EP4023250A1 (en) * | 2021-01-04 | 2022-07-06 | Technische Universität München | Dual mode radiotracer and -therapeutics |
| US20240165281A1 (en) | 2021-02-15 | 2024-05-23 | Technische Universität München | Dual mode radiotracer and therapeutics |
| US20240181092A1 (en) * | 2021-04-02 | 2024-06-06 | Novartis Ag | Diagnostic methods of prostate cancer |
| KR20240008341A (ko) * | 2021-05-14 | 2024-01-18 | 테크니쉐 유니베르시테트 뮌헨 | 방사성약제학적 소마토스타틴 수용체 리간드 및 그의 전구체 |
| GB202108779D0 (en) | 2021-06-18 | 2021-08-04 | Blue Earth Diagnostics Ltd | Si-at therapeutic/diagnostic compounds |
| GB202109922D0 (en) | 2021-07-09 | 2021-08-25 | Blue Earth Diagnostics Ltd | Radiotracers and therapeutics binding to fibroblast activation protein (fap) |
| IL310066A (en) * | 2021-08-05 | 2024-03-01 | Technische Universit?T M?Nchen | Ligand compounds comprising a chelating group as a bridging group |
| GB202113646D0 (en) | 2021-09-24 | 2021-11-10 | Blue Earth Diagnostics Ltd | Method of preparation of 18F labelled silyl-fluoride compounds |
| CN114671806B (zh) * | 2022-04-08 | 2024-03-01 | 上海如絮生物科技有限公司 | 一种亲水性吡啶衍生物、中间体、其制备方法及应用 |
| GB202207372D0 (en) | 2022-05-19 | 2022-07-06 | Blue Earth Diagnostics Ltd | Synthesis of fluorosilyl compounds |
| CA3257852A1 (en) | 2022-07-29 | 2024-02-01 | Technische Universitat Munchen | Silicon Fluoride Accepting Groups for Radiopharmaceutical Products |
| WO2024054226A1 (en) * | 2022-09-06 | 2024-03-14 | Hoang Ba Xuan | Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment |
| JP2025532619A (ja) * | 2022-09-20 | 2025-10-01 | テクニシェ ユニバーシタット ミュンヘン | イメージングおよび標的化放射線治療のための新規ミニガストリン由来コレシストキニン２受容体結合分子 |
| AU2023347470A1 (en) | 2022-09-23 | 2025-04-10 | Nuclidium Ag | High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof |
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| AU2023379454A1 (en) * | 2022-11-14 | 2025-05-29 | Aktis Oncology, Inc. | Decreased retention of miniproteins in kidney |
| TW202530249A (zh) | 2023-09-29 | 2025-08-01 | 美商雅克提斯腫瘤學公司 | 小蛋白、結合物及其用途 |
| GB202316239D0 (en) | 2023-10-24 | 2023-12-06 | Blue Earth Diagnostics Ltd | Therapeutic combination |
| WO2025250644A1 (en) * | 2024-05-28 | 2025-12-04 | Case Western Reserve University | Fluorescent nuclide-containing agents for detecting and treating cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7384394A (en) * | 1993-06-30 | 1995-01-24 | Akzo Nobel N.V. | Chelating compounds |
| WO2003011345A1 (en) | 2001-07-27 | 2003-02-13 | Targesome, Inc. | Lipid constructs as therapeutic and imaging agents |
| CN102626522B (zh) * | 2012-04-12 | 2014-09-10 | 韩彦江 | 基于趋化因子受体cxcr4多肽类拮抗剂的多肽放射性诊断与治疗药物 |
| CN106794264B (zh) * | 2014-06-10 | 2021-03-23 | 3B制药有限公司 | 包含神经降压肽受体配体的缀合物及其用途 |
| EP3209336B1 (en) | 2014-10-20 | 2019-12-11 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| US20160287730A1 (en) * | 2015-03-31 | 2016-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Labeled evans blue dye derivative for in vivo serum albumin labeling |
| CN107667109B (zh) * | 2015-05-26 | 2021-08-03 | 加利福尼亚大学董事会 | 可用于分子和生物分子的18f标记的新的杂芳族硅-氟化物-受体及其制备方法 |
| EA202090370A1 (ru) | 2017-07-28 | 2020-05-25 | Технише Универзитет Мюнхен | Двухрежимная радиоактивная метка и радиотерапевтическое средство |
| BR112020011727A2 (pt) * | 2017-12-11 | 2020-11-17 | Technische Universität München | ligantes de psma para imageamento e endorradioterapia |
| IL303420A (en) | 2019-01-30 | 2023-08-01 | Univ Muenchen Tech | Diagnostic imaging materials for cancer |
| EP3917626B1 (en) | 2019-01-30 | 2023-05-31 | Technische Universität München | Psma binding dual mode radiotracer and therapeutic |
-
2018
- 2018-07-30 EA EA202090370A patent/EA202090370A1/ru unknown
- 2018-07-30 ES ES18743540T patent/ES3011272T3/es active Active
- 2018-07-30 JP JP2020526688A patent/JP7059372B2/ja active Active
- 2018-07-30 EP EP22150556.3A patent/EP4000640A1/en not_active Withdrawn
- 2018-07-30 KR KR1020207005589A patent/KR102752620B1/ko active Active
- 2018-07-30 NZ NZ760537A patent/NZ760537A/en unknown
- 2018-07-30 EP EP24184312.7A patent/EP4424378A3/en active Pending
- 2018-07-30 BR BR112020001785-0A patent/BR112020001785A2/pt unknown
- 2018-07-30 HU HUE18743540A patent/HUE070098T2/hu unknown
- 2018-07-30 CN CN201880062949.0A patent/CN111132700B/zh active Active
- 2018-07-30 DK DK18743540.9T patent/DK3658194T3/da active
- 2018-07-30 AU AU2018308699A patent/AU2018308699B2/en active Active
- 2018-07-30 CA CA3071315A patent/CA3071315A1/en active Pending
- 2018-07-30 MX MX2020000352A patent/MX2020000352A/es unknown
- 2018-07-30 PT PT187435409T patent/PT3658194T/pt unknown
- 2018-07-30 SG SG11202000725WA patent/SG11202000725WA/en unknown
- 2018-07-30 KR KR1020247006169A patent/KR20240027896A/ko not_active Ceased
- 2018-07-30 FI FIEP18743540.9T patent/FI3658194T3/fi active
- 2018-07-30 US US16/634,759 patent/US11413360B2/en active Active
- 2018-07-30 EP EP18743540.9A patent/EP3658194B1/en active Active
- 2018-07-30 IL IL318092A patent/IL318092A/en unknown
- 2018-07-30 PL PL18743540.9T patent/PL3658194T3/pl unknown
- 2018-07-30 WO PCT/EP2018/070533 patent/WO2019020831A1/en not_active Ceased
- 2018-07-30 IL IL272291A patent/IL272291B2/en unknown
-
2020
- 2020-01-10 MX MX2023007914A patent/MX2023007914A/es unknown
- 2020-01-23 ZA ZA2020/00467A patent/ZA202000467B/en unknown
-
2022
- 2022-04-12 JP JP2022065524A patent/JP2022101601A/ja active Pending
- 2022-06-24 US US17/849,297 patent/US12390540B2/en active Active
-
2024
- 2024-01-24 AU AU2024200440A patent/AU2024200440B2/en active Active
- 2024-11-15 US US18/948,808 patent/US12453787B2/en active Active
-
2025
- 2025-09-24 US US19/338,850 patent/US20260021211A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2024200440B2 (en) | Dual mode radiotracer and -therapeutics | |
| JP7393485B2 (ja) | 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用 | |
| CN113573743B (zh) | 癌症诊断成像剂 | |
| CN113677400B (zh) | 结合psma的双模式放射性示踪剂及治疗剂 | |
| KR20230160806A (ko) | 이중 모드 방사성 트레이서 및 치료법 | |
| WO2022018264A1 (en) | Silicon-containing ligand compounds | |
| HK40022705A (en) | Dual mode radiotracer and -therapeutics | |
| HK40022705B (en) | Dual mode radiotracer and -therapeutics | |
| EA046402B1 (ru) | Двухрежимная радиоактивная метка и радиотерапевтическое средство | |
| EA052134B1 (ru) | Двухрежимная радиоактивная метка и радиотерапевтическое средство |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230614 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240729 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240729 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240729 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240813 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241212 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250206 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250612 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250612 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250725 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250725 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260408 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260408 |